Aminoglycoside

Aminoglycosides are broad-spectrum antibacterial compounds whose major target is the bacterial ribosome, where treatment decreases protein synthesis by repressing initiation and elongation[1]. Mechanistically, aminoglycosides bind determinants in the 16S rRNA A site and ribosomal proteins, causing messenger RNA decoding errors, blocking mRNA-tRNA translocation, and inhibiting ribosome recycling[1][2]. In Escherichia coli 70S ribosome structures, aminoglycoside binding to helix H69 restored intersubunit contacts disrupted by ribosome recycling factor, providing a structural basis for recycling inhibition[2]. Disease relevance centers on serious bacterial infections, where aminoglycosides remain medically important, but resistance limits experimental and clinical utility[3][4]. Compared with related antibacterial classes, aminoglycosides show target-specific resistance through aminoglycoside-modifying enzymes, altered transport, ribosomal mutation, and 16S rRNA methylation[1][4][5]. Compared with streptomycin, 16S rRNA methylation confers high-level resistance to clinically available systemic aminoglycosides except streptomycin, distinguishing isoform-like class behavior within aminoglycoside agents[5]. For experimental applications, kanamycin derivatives modified by resistance enzymes showed diminished binding to bacterial 16S rRNA A-site RNA, linking chemical modification, target affinity, and antibacterial loss[6].